Skip to Main Content
Welcome to the Marketplace

Go to Main Navigation


Year Established:
Company Type:
Small Business (1-10M TTM Revenue)

Curesponse’s ex vivo organ culture technology entitled cResponse™ was developed together with the Weizmann Institute of Science. The platform enables growing of human tumors in their native tumor microenvironment, allowing for accurate prediction of drug response. The The Curesponse laboratory is ISO 15189 approved for both genomics and functional tests. The cResponse™ treatment selection assay, has been validated on animal models of cancer (PDX). In addition, clinical validation of cResponse on different indications, testing a large variety of drugs, is ongoing at several medical centers with encouraging preliminary results.

Site Badges
Oppenheimer 2 Rehovot , , 9348930 Israel

Get started

To request access, simply fill out the form below and we will contact you.

Password must:

• Be at least 12 characters in length

• Contain a lowercase letter (a-z)

• Contain an uppercase letter (A-Z)

• Contain a numeral (0-9)

• Contain a special character (%, $, !, @)

By signing up for this account you agree to the Terms of Service